BLIS Technologies (NZSE:BLT) ROE % Adjusted to Book Value: 3.02% (As of Mar. 2026)


What is BLIS Technologies ROE % Adjusted to Book Value?

BLIS Technologies NZSE:BLT +6.25% ROE % Adjusted to Book Value is 3.02% as of Mar. 2026. The stock has 4 warning signs investors should review.

BLIS Technologies's ROE % for the quarter that ended in Mar. 2026 was 4.23%. BLIS Technologies's PB Ratio for the quarter that ended in Mar. 2026 was 1.40. BLIS Technologies's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 3.02%.

BLIS Technologies ROE % Adjusted to Book Value Related Terms

BLIS Technologies ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for BLIS Technologies's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BLIS Technologies ROE % Adjusted to Book Value Chart

BLIS Technologies Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.41 -3.65 3.06 5.03 3.90

BLIS Technologies Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.86 2.74 7.24 4.18 3.02

NZSE:BLT vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, BLIS Technologies's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BLIS Technologies ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BLIS Technologies's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where BLIS Technologies's ROE % Adjusted to Book Value falls into.


BLIS Technologies ROE % Adjusted to Book Value Calculation

BLIS Technologies's ROE % Adjusted to Book Value for the fiscal year that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=5.46% / 1.40
=3.90%

BLIS Technologies's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=4.23% / 1.40
=3.02%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 3.02% mean?
BLIS Technologies (NZSE:BLT) has a ROE % Adjusted to Book Value of 3.02% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BLIS Technologies and its competitors.
Is BLIS Technologies' ROE % Adjusted to Book Value too high?
BLIS Technologies' current ROE % Adjusted to Book Value is 3.02%.
How does BLIS Technologies' ROE % Adjusted to Book Value compare to VRTX and REGN?
BLIS Technologies' ROE % Adjusted to Book Value of 3.02% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BLIS Technologies and its competitors. BLIS Technologies's current ROE % Adjusted to Book Value is 3.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLIS Technologies stock overvalued right now?
Based on GuruFocus' analysis, BLIS Technologies (NZSE:BLT) is currently considered Modestly Undervalued. The stock's GF Value™ is NZ$0.02, compared to a current price of NZ$0.02 — trading 15% below its estimated fair value. The current ROE % Adjusted to Book Value is 3.02%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For BLIS Technologies (NZSE:BLT), the current ROE % Adjusted to Book Value is 3.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BLIS Technologies Business Description

Address 399 Moray Place, Dunedin Central, Dunedin, OTA, NZL, 9016
BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18, which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from North America. The company also generates a small portion of revenue from Non-core business, which includes grants and interest revenue.